Aura Biosciences, Inc. Logo

Aura Biosciences, Inc.

Developing virus-like therapies to selectively destroy solid tumors in ocular & urologic oncology.

AURA | US

Overview

Corporate Details

ISIN(s):
US05153U1079
LEI:
Country:
United States of America
Address:
80 GUEST STREET, 2135 BOSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Aura Biosciences, Inc. is a clinical-stage biotechnology company developing a novel class of targeted cancer therapies. The company's proprietary Virus-Like Drug Conjugate (VDC) platform uses Virus-Like Particles (VLPs) to selectively target and destroy solid tumor cells while aiming to preserve healthy tissue. Aura's initial focus is on indications with significant unmet medical needs, particularly in ocular and urologic oncology. Its lead clinical program is being evaluated as a potential first-line treatment for early-stage choroidal melanoma, a rare eye cancer where current treatments often result in vision loss.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Aura Biosciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aura Biosciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aura Biosciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Sarepta Therapeutics, Inc. Logo
Develops precision genetic medicines for rare neuromuscular disorders.
United States of America SRPT
Savara Inc Logo
Clinical-stage biopharma developing inhaled therapies for rare respiratory diseases.
United States of America SVRA
SAWAI GROUP HOLDINGS Co., Ltd. Logo
A leading Japanese generic drug maker expanding into digital health and wellness solutions.
Japan 4887
Scandion Oncology A/S Logo
Biotech company in liquidation, formerly developing therapies to overcome cancer drug resistance.
Denmark SCOL
Scholar Rock Holding Corp Logo
Biopharma developing medicines for neuromuscular diseases by targeting protein growth factors.
United States of America SRRK
Scienture Holdings, Inc. Logo
Develops and commercializes specialty drugs for unmet medical needs, focusing on CNS disorders.
United States of America SCNX
Scilex Holding Co Logo
Develops and commercializes non-opioid products for acute and chronic pain management.
United States of America SCLX
Scinai Immunotherapeutics Ltd. Logo
Dual-model biopharma: developing NanoAbs for I&I and offering CDMO services.
United States of America SCNI
SciSparc Ltd. Logo
Developing cannabinoid-based therapies for central nervous system (CNS) disorders.
United States of America SPRC
Develops high-purity stem cell therapies for incurable immunological and inflammatory diseases.
South Korea 298060

Talk to a Data Expert

Have a question? We'll get back to you promptly.